• 71.4% of MetaXplore™ reports identified actionable results
• 41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health
• 65% of patients reported health improvements following clinician-directed recommendations

Microba Life Sciences Ltd (ASX: MAP) has announced preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders. The study found that 71.4% of the reports identified actionable results, with 41.9% showing abnormal microbiome markers linked to gastrointestinal health, including 7% that were positive for a pathogen species that can cause GI infection. Additionally, 9.9% of reports tested positive for a gastrointestinal marker, such as inflammation, pancreatic insufficiency, or faecal occult blood, prompting further diagnostic workup. 19.6% of reports tested positive for multiple markers, requiring a personalized mix of pharmacological, nutritional, and lifestyle modification strategies. In a separate study, 65.5% of 84 patients who received MetaXplore-guided care reported health improvements, with 22.6% reporting significant improvement and 42.9% noticing some improvement. An in-depth analysis estimated an addressable population of 82.2 million patients across the US, Germany, Italy, Spain, France, the United Kingdom, and Australia with chronic diarrhea or non-specific abdominal symptoms, including those characterized with Irritable Bowel Syndrome (IBS) or diagnosed with Inflammatory Bowel Disease (IBD). The results highlight the clinical value of MetaXplore in advancing outcomes for patients with chronic lower gastrointestinal disorders and the potential to reshape the standard of care for these conditions.

The company estimates an addressable population of 82.2 million patients across the US, Germany, Italy, Spain, France, the United Kingdom, and Australia with chronic diarrhea or non-specific abdominal symptoms, including those characterized with Irritable Bowel Syndrome (IBS) or diagnosed with Inflammatory Bowel Disease (IBD).